Single-cell analysis reveals clonally expanded tumor-associated CD57 <sup>+</sup> CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade
Michael Fehlings(University of Toronto), Mahesh Yadav(University of Florida), Sanjeev Mariathasan(Kaiser Permanente San Francisco Medical Center), Alireza Tafazzol, Leesun Kim(Ulsan National Institute of Science and Technology), Siming Ma(Brigham and Women's Hospital), Shomyseh Sanjabi(University of California, San Francisco), Ana Milojkovic(Seascape Consultants (United Kingdom)), Kobe Yuen(La Roche College), Evan W. Newell(Agency for Science, Technology and Research), Andrew J. Wallace(St Mary's Hospital), Xiangnan Guan(Unknown), Deepali Rishipathak, Alessandra Nardin(Singapore Immunology Network), Oliver A. Zill(Guardant (United States))
Cited by 55
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection
|Cold Spring Harbor Perspectives in Biology|2017|606